I am definitely not happy with a 54% drop in the price. 

While it does bother me, I remind myself of why I got into this stock years ago.  It was because the cancer detection technology they were working on, had the potential to help so many people in this world.  People like my family, friends and coworkers that found out about their cancer late in the game. 

Yes, I would like to make profits, and lots of it too, but that isn't why I got into this stock.  I am sure the profits will come.  Maybe not today or tomorrow, or even this year, but it will come.

Am I looking at the revenues generated by Covid testing as a recurring revenue?  No.  In fact, I would not count on it after Q2 in my personal analysis, because I like to be conservative in my computations.  What matters to me right now is to see (i) steady growth in the revenues from cancer testing (and likely treatment now), (ii) new partnerships that SZLS forge, (iii) expansion of cancer testing in the US, and then into Canada and Europe, and (iv) more transparency and timely communications from SZLS.  

And to those that keep saying "net profits" from each Aristotle test, it's actually gross profits.  Let's not get too excited that it is actual net profits.  It is not the bottom line, it only contributes to the bottom line.

And as far as Care Oncology is concerned, they may or may not be happy with the drop in share price, but I am quite sure they were not looking so much at the price today, but at what it could be in the future.  They will have a substantial say at the AGM, with voting for the BOD, and with the day to day operations going forward, assuming the deal closes successfully.  So don't assume that things will not change, or that James will keep doing things as he has done in the past.


Cheers!